4142:TPE
Adimmune Corp
NT$16.80
arrow_upward
+0.60%(+0.100) 1 دن
13 نومبر, 12:19:00 PM GMT +8 · TWD
search
تمام علامات
| علامت | قیمت | تبدیلی | % تبدیلی |
|---|
insights_auto4142 کے لیے سرفہرست بصیرتیں تخلیق کی جا رہی ہیں...
کھولیں
NT$16.85
اعلی
NT$17.15
کم
NT$16.75
مارکیٹ کی سرمایہ کاری
7.22 ارب
اوسط والیوم
11.29 لاکھ
والیوم
6.49 لاکھ
52 ہفتے میں اعلی
NT$22.50
52 ہفتے کا کم
NT$15.65
EPS
-NT$0.34
بقایہ شیئرز
23.53 کروڑ
ملازمین کی تعداد
564
کھولیں
NT$16.85
اعلی
NT$17.15
کم
NT$16.75
مارکیٹ کی سرمایہ کاری
7.22 ارب
اوسط والیوم
11.29 لاکھ
والیوم
6.49 لاکھ
52 ہفتے میں اعلی
NT$22.50
52 ہفتے کا کم
NT$15.65
EPS
-NT$0.34
بقایہ شیئرز
23.53 کروڑ
ملازمین کی تعداد
564
خبریں اور کہانیاں
ویب ذرائع اور خبروں کے پارٹنرز سے
TradingView
·
1 گھنٹہ پہلے
Dow, S&P 500, Nasdaq Futures Edge Higher As Markets Attempt To Recover From Nvidia Rout: SLS, MSFT, CADL, MSTR In Focus
Eurasia Business News
·
4 گھنٹے پہلے
Stock Market Today, November 12, 2026: Dow, S&P 500 and Nasdaq Fall After Jensen Huang Resigns
ChartMill
·
9 گھنٹے پہلے
Most Active S&P 500 Stocks: KDP, Ford, AT&T Lead Today's Session
Traders Union
·
6 گھنٹے پہلے
Jake Wujastyk: S&P 500 and ES_F trade within last Thursday's range for a full week
پروفائل
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Adimmune Corp کے بارے میں